SQ HDM SLIT-tablet is effective in patients not well-controlled in GINA treatment steps 2-4

Johann Christian Virchow (Rostock, Germany), Johann Christian Virchow, Victoria Cardona, Hanne Villesen, Christian Ljørring, Bente Riis, Frederic de Blay

Source: International Congress 2016 – Asthma management
Session: Asthma management
Session type: Thematic Poster
Number: 4108
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Johann Christian Virchow (Rostock, Germany), Johann Christian Virchow, Victoria Cardona, Hanne Villesen, Christian Ljørring, Bente Riis, Frederic de Blay. SQ HDM SLIT-tablet is effective in patients not well-controlled in GINA treatment steps 2-4. Eur Respir J 2016; 48: Suppl. 60, 4108

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014


P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016

Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Source: International Congress 2016 – Asthma management
Year: 2016


Tiotropium for uncontrolled asthma (a meta-analysis)
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013



Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016


Outcomes with omalizumab in Indian patients with allergic (IgE-mediated) asthma: Results at 16 and 28 weeks
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013


First clinical trial of a new IgE-adsorber in allergic asthma
Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma
Year: 2015

Asthma control, symptoms and exacerbations across treatment levels in patients with asthma
Source: Annual Congress 2013 –Management of respiratory diseases in primary care
Year: 2013


Total and free IgE in evolution of severe asthma after omalizumab treatment
Source: International Congress 2016 – Asthma management
Year: 2016


Omalizumab add-on therapy reduces exacerbations among responders: A pooled NNT analysis from 5 phase 3 studies
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014


Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015

Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study
Source: International Congress 2016 – Asthma points to ponder
Year: 2016

Finding asthmatics suitable for omalizumab therapy in a district hospital
Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment?
Year: 2013


Allergic versus non allergic asthma: What makes the difference?
Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms
Year: 2015

Asthma control is reached in a large majority of asthmatics treated with omalizumab. An Italian observational study
Source: Annual Congress 2013 –Disease control and quality of life in airway diseases
Year: 2013


Evaluating omalizumab persistency of response after long-term therapy (XPORT)
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014


Clinical outcomes in non-eosinophilic versus eosinophilic asthma after 12 months specialist management
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015

FeNO in children with asthma is related to inhaled corticosteroids adherence, not to asthma control
Source: International Congress 2014 – Paediatric asthma: markers and molecules
Year: 2014

Omalizumab reduces exacerbations and healthcare utilisation in severe allergic asthma patients UK clinical practice - APEX II study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014


Adherence to the treatment of patients with bronchial asthma
Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage?
Year: 2015